Atropos Health Announces $33M Series B Round
Summary
PALO ALTO, CA, Atropos Health today announced a $33 million Series B on the heels of the adoption of its Generative AI platform. Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OS) by healthcare institutions, data platforms, research institutions, life sciences companies and more. Atropos Health is the developer of the first physician consultation service powered by research-grade real-world data. Using millions of anonymized patient records, Atropos helps providers answer clinical questions that have fallen through the cracks of the evidence-based literature. By leveraging insights from free-text notes and other non-standard data entries that often go overlooked, Atropos empowers more robust research and effective care delivery.
Funding
Review available funding amount, funding date, investors, and linked company information related to Atropos Health Announces $33M Series B Round in the interactive ISVWorld profile.